



Agile Therapeutics  
Investor Relations Department  
101 Poor Farm Road  
Princeton, NJ 08540  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: AGRX**

|               |  |
|---------------|--|
| Last Trade:   | 2.92   |
| Trade Time:   | 4:00 PM ET<br>Mar 19, 2018                         |
| Change:       | -0.11 <span style="color: red;">▼</span> (-3.630%) |
| Day Range     | 2.90 - 3.17  |
| 52-Week Range | 1.93 - 5.60  |
| Volume        | 143,097  |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

Our lead product candidate, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is based on our proprietary transdermal patch technology called Skinfusion® which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

## Stock Performance



## Press Releases [\[ View all \]](#)

Mar 14, 2018

[Abstract on AG200-15 \(Twirla®\) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition](#)

Mar 12, 2018

[Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results](#)

Dec 22, 2017

[Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® \(AG200-15\) for the Prevention of Pregnancy](#)

Nov 6, 2017

[Agile Therapeutics Reports Third Quarter 2017 Financial Results](#)

Oct 31, 2017

[Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine \(ASRM\) Scientific Congress & Expo 2017](#)

## Financials [\[ View all \]](#)

Mar 12, 2018

[Annual Report \(10-K\)](#)

Apr 24, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017

[Quarterly Report \(10-Q\)](#)

Jul 28, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)